



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## Application for a Module B Type-Examination Certificate

In accordance with the Personal Protective Equipment Regulation (EU) 2016/425 and or Regulation 2016/425 on personal protective equipment, as amended to apply in GB. Hereafter referred to as the PPE Regulation.

This application and the subsequent certification will only address the obligations under the PPE Regulation. It is the responsibility of the manufacturer to ensure that all other legislative requirements and claims, including those relating to shelf life are met.

Please note that all relevant sections of this application should be completed in full. Failure to complete all relevant sections shall result in the rejection of this application.

Please indicate which Notified Body and or Approved Body this application relates. Where the application is for both EU and UKCA type examination then please tick both.

SATRA Technology Europe Limited Notified Body 2777	<b>EU Type Examination</b>	<input checked="" type="checkbox"/>
SATRA Technology Centre Limited Approved Body 0321	<b>UKCA Type Examination</b>	<input type="checkbox"/>

### Guidance on the completion of this form

Application type	Tick to indicate application type	Sections to be completed	Submission requirements
All applications		Section 1 Section 7	<ul style="list-style-type: none"> <li>Completed and signed application form</li> </ul>
Initial type-examination certificate	<input type="checkbox"/>	Section 2 Section 6	<ul style="list-style-type: none"> <li>Example of product (s)</li> <li>Complete technical documentation as per Annex III of the PPE Regulation. See guidance below for required content</li> <li>Completed module C2/D application, where applicable</li> </ul>
Review of existing type-examination certificate	<input type="checkbox"/>	Section 3	<ul style="list-style-type: none"> <li>Example of products (s) where significant changes have been identified.</li> <li>Amendments to technical documentation</li> </ul>
Transfer of existing type-examination certificate	<input type="checkbox"/>	Section 4 Section 6	<ul style="list-style-type: none"> <li>Example of product (s) where not previously seen by SATRA.</li> <li>Copy of the approved technical documentation as per Annex III of the PPE Regulation. See guidance below for required content</li> <li>Copy of certificate to be transferred</li> <li>Completed module C2/D application, where applicable</li> </ul>
Own brand manufacturer/extension type-examination certificate	<input checked="" type="checkbox"/>	Section 5 Section 6	<ul style="list-style-type: none"> <li>Copy of OBM proposed artwork for user information, product marking and packaging.</li> <li>Completed module C2/D application, where applicable</li> </ul>



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## Guidance on the technical documentation required by Annex III of the PPE Regulation

The information below has been copied from Annex III of the PPE regulation and is intended to provide guidance on the content of technical documentation (often referred to as the technical file) that is required to be submitted as part of the type examination application. SATRA can provide upon request a template technical file to aid with the collation of the required documentation.

- a) A complete description of the PPE and of its intended use;
- b) An assessment of the risks against which the PPE is intended to protect;
- c) A list of the essential health and safety requirements that are applicable to the PPE;
- d) Design and manufacturing drawings and schemes of the PPE and of its components, sub-assemblies, and circuits;
- e) Any explanations necessary for the understanding of the drawings and schemes referred to in point (d) and of the operation of the PPE;
- f) The references of the harmonised standards referred to in Article 14 that have been applied for the design and manufacture of the PPE. In the event of partial application of harmonised standards, the documentation shall specify the parts which have been applied;
- g) Where harmonised standards have not been applied or have been only partially applied, descriptions of the other technical specifications that have been applied in order to satisfy the applicable essential health and safety requirements; the results of the design calculations, inspections and examinations carried out to verify the conformity of the PPE with the applicable essential health and safety requirements;
- h) Reports on the tests carried out to verify the conformity of the PPE with the applicable essential health and safety requirements and, where appropriate, to establish the relevant protection class;
- i) A description of the means used by the manufacturer during the production of the PPE to ensure the conformity of the PPE produced with the design specifications;
- j) A copy of the manufacturer's instructions and information set out in point 1.4 of Annex II;
- k) For PPE produced as a single unit to fit an individual user, all the necessary instructions for manufacturing such PPE based on the approved basic model;
- l) For PPE produced in series where each item is adapted to fit an individual user, a description of the measures to be taken by the manufacturer during the fitting and production process to ensure that each item of PPE complies with the approved type and with the applicable essential health and safety requirements.



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## **Section 1 – Applicant details**

### **Section 1.1 Applicant**

Details of the applicant to whom the certificates are to be issued, or in the case of an extension application the holder of the main type-examination certificate.

<b>Company Name</b>	Shijiazhuang Hongray Group Co., Ltd.		
<b>Address Line 1</b>	South Tongda Road, East District Jinzhou City, Hebei, 052260, China		
<b>Address Line 2</b>			
<b>City</b>	Jinzhou	<b>Country</b>	China
<b>County/State/Province</b>	Hebei	<b>Postal Code / ZIP</b>	052260
<b>Telephone</b>	8617732123968	<b>Email</b>	renmin@hongray.com.cn
<b>Contact Name</b>	RENMIN	<b>Position</b>	QA

All correspondence relating to this application shall be with the above-named applicant, unless specifically stated below.

### **Section 1.2 Correspondence**

I request that correspondence relating to this application is to be shared with the following company(ies)/contact(s):

<b>Company Name</b>	<b>Contact Name</b>	<b>Email Address</b>
Setino Hungary Kft	LIU JIN	Grace@setino.com

Where additional correspondence has been requested then this shall be on a shared basis.




**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

### Section 1.3 – Invoice details (to be completed if different to the applicant in section 1.1)

Details of the company that is responsible for paying all fees and to whom the invoice shall be issued. Correspondence shall only be with the applicant listed in section 1.1 plus any additional contacts provided in section 1.2.

<b>Company Name</b>	Setino Hungary Kft		
<b>Relationship to applicant</b>	Customer		
<b>Address Line 1</b>	Budapest, Száva u. 4B, 1107		
<b>Address Line 2</b>			
<b>City</b>	Budapest	<b>Country</b>	Hungary
<b>County/State/Province</b>	Hungary	<b>Post Code / ZIP</b>	1107
<b>Telephone</b>	+36704065340	<b>Email</b>	Grace@setino.com
<b>Contact Name</b>	LIU JIN	<b>Position</b>	Manager Assistant

I have read and agree to the applicable declarations listed under section 7 of this form.			
<b>Signature</b>	 SETINO HUNGARY KFT. 1107 Budapest, Száva u. 4/B Adószám: 13337634-2-42	<b>Date</b>	2023.6.8
<b>Print Name</b>	LI LI	<b>Position</b>	General Manager







**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

### **Section 3 - Application for review of existing type examination**

Details of and reason(s) of the certificate to be reviewed

<b>Certificate Number(s) <sup>(1)</sup></b>	<b>Reason for review <sup>(2)</sup></b>
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)
	Choose an item.
	Details of the change(s)

Please submit all amendments to technical documentation relating to the above certificate(s) as well as additional test reports and photographs where applicable with this application.

Please list all changes that you wish to be considered as part of this application. Only these changes shall be considered.

Where the application relates to expiry of a certificate and there have been no modifications or changes to the approved technical documents or products since the issue of the type examination certificate(s), (e.g., design, materials, suppliers, sub-components/assemblies, production locations) then please write "no changes"

Where there is an Own Brand Manufacturer (OBM) (extension) certificate associated with any of the above listed certificates then consideration shall be given to their ongoing validity and where appropriate an extension application completed and submitted.

#### **Notes**

- (1) Please include the numbers of all certificates that require review.
- (2) Please select the option that relates to the reason for the review being required.



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## **Section 4 – Application for transfer of existing type-examination**

Details of the certificate(s) to be transferred, including where not SATRA details of the issuing body.

Certificate Number	Product Reference <sup>(1)</sup>	Name of Notified or Approved body that issued certificate (if not SATRA)

Have there been any modifications or changes to the approved technical documents or products since the issue of the type examination certificate(s)? (e.g., design, materials, suppliers, sub-components/assemblies, production locations)	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
If yes, then please provide further details of the changes and or modifications				

### Notes

- 1) The reference, code, or name by which products can be uniquely identified.



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## **Section 5 – Application for Own Brand/Extension of existing type-examination**

### **Section 5.1 Extension certificate details (Company to receive the extension certificate)**

<b>Company Name</b>	Setino Hungary Kft		
<b>Address Line 1</b>	Budapest, Száva u. 4B, 1107		
<b>Address Line 2</b>			
<b>City</b>	Budapest	<b>Country</b>	Hungary
<b>County/State/Province</b>	Hungary	<b>Postal Code / ZIP</b>	1107
<b>Telephone</b>	+36704065340	<b>Email</b>	grace@setino.com
<b>Contact Name</b>	LIU JIN	<b>Position</b>	Manager Assistant

### **Section 5.2 – Certificate details**

<b>Original certificate number(s)</b>	<b>Original certificate product reference(s)</b>	<b>Extension (OBM) product reference(s)</b>
2777/14615-03/E00-00	NPF3001-3006 Violet Blue NPF5001-5006 White	Disposable Nitrile Gloves, Powder-free Color: Violet Blue XS: NPF3001 S: NPF3002 M: NPF3003 L: NPF3004 XL: NPF3005 XXL: NPF3006



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

### Section 5.3 Extension application declaration.

To be signed by the company to whom the extension type-examination certificate will be issued.

I, the undersigned:

- 1) Confirm that the extension certificate(s) will only be used to support the affixation of the CE or UKCA mark to products that have been supplied by the holder of the Module B Type Examination Certificate(s) referenced in Section 1 above and declared by them to have been manufactured in accordance with the technical documentation associated with the referenced Module B type-examination certificate(s) in section 5.2.
- 2) Confirm that for Category III products, a formal application regarding Module C2 or Module D assessment, as appropriate has been established with a Notified or Approved Body. (Note this could be based on an existing application between the company in Section 1 and a Notified or Approved Body)
- 3) Agree to provide copies of the proposed product marking and user information as intended for the products covered by the extension certificate(s).

I have read and agree to the declarations listed above and within section 7 of this form.

<b>Signature</b>	<b>SERINO HUNGARY KFT.</b> 1107 Budapest, Száva u. 4/B Adószám: 13337634-2-42	<b>Date</b>	2023.6.8
<b>Print Name</b>	LI LI	<b>Position</b>	General Manager



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## **Section 6 – Ongoing conformity**

To be completed for category III products only (as defined in Annex I of the PPE Regulation)  
 Please tick and complete one of the 4 following options

<b>Option 1</b>	Module C2 with SATRA	<input checked="" type="checkbox"/>
<b>Option 2</b>	Module D with SATRA (Module D not currently in place with SATRA)	<input type="checkbox"/>
<b>Option 3</b>	Module D with SATRA (Module D currently in place with SATRA)	<input type="checkbox"/>
<b>Option 4</b>	Module C2 or D with another Notified or Approved body (i.e., Not SATRA) Please include Notified or Approved body number	<input type="checkbox"/>

Where a Notified or Approved Body other than SATRA is selected for ongoing conformity then it should be noted that SATRA CANNOT approve the use of the Notified or Approved Body number on marking, user information or packaging. The applicant is required to seek approval directly from the body listed above. SATRA reserves the right to ask for evidence of approval.

Where options 1 or 2 are selected a separate application shall be provided, this shall be required to be completed and returned prior to the type examination certificate being issued.

### **Definition of products that fall within Category III as per Annex I of the PPE Regulation**

- a) substances and mixtures which are hazardous to health;
- b) atmospheres with oxygen deficiency;
- c) harmful biological agents;
- d) ionising radiation;
- e) high-temperature environments the effects of which are comparable to those of an air temperature of at least 100 °C;
- f) low-temperature environments the effects of which are comparable to those of an air temperature of – 50 °C or less;
- g) falling from a height;
- h) electric shock and live working;
- i) drowning;
- j) cuts by hand-held chainsaws;
- k) high-pressure jets;
- l) bullet wounds or knife stabs;
- m) harmful noise.






**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## **Section 7 – Declaration**

- 1) I declare that an application for an initial Module B type-examination certification for the product(s) listed in this form has NOT been made to any other Notified or Approved Body under the terms of the PPE Regulation;
- 2) I understand that all technical documentation shall be reviewed at the same time. SATRA cannot accept requests to review or comment on individual documents outside of this formal review.
- 3) I agree to provide an example of the product(s) listed in this form as part of the initial application plus as many samples as required for testing purposes identified as part of the certification process and where SATRA is the test lab;
- 4) I confirm that samples comply with the innocuousness requirements of Annex II of the PPE Regulation;
- 5) I confirm that I have read, understood, and agree to abide by the content of the certification agreement included as Appendix 1 of this document;
- 6) I declare that SATRA have not been involved in the design process for the product(s) listed in this form;
- 7) I agree to comply with all obligations of a manufacturer as detailed in Article 8 of the PPE Regulation (and as copied out under section 5 of the certification agreement);
- 8) I agree that technical information and documents relating to this application may be shared internally within the SATRA group of companies;
- 9) I agree to address all findings identified within SATRA's review report(s) within 3 months of the date of issue of the report;
- 10) I agree that failure to address all findings within the required timeframe shall be assumed by SATRA as a wish to cancel this application which shall result in closure of the associated SATRA reference number, at which point, an invoice shall be issued for the full certification cost. Any associated payments received in relation to this application are non-refundable and non-transferable. Please note that upon cancellation, any product samples submitted to SATRA in relation to this application shall be disposed;
- 11) I agree that any request to resume a cancelled application shall require the submission of a new application.

To be completed by the applicant as listed in section 1.1.

<b>Signature</b>		<b>Date</b>	2023.6.7
<b>Print Name</b>	RENMIN	<b>Position</b>	QA

**Please return the completed application form, together with a copy of your technical documentation to [ppe@satra.com](mailto:ppe@satra.com).**

**Guidance relating to the submission of samples will be provided upon receipt of this application by SATRA.**



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

## Appendix 1 – Certification agreement

### 1. General

- 1.1 By signing this application form, the applicant (hereafter known as the 'Client') shall accept the application and Certification Agreement as a legally binding contract between SATRA Technology Centre Limited and or SATRA Technology Europe Ltd (hereafter referred as 'SATRA') and the 'Name of company' as stated in the 'Applicant Details' on Page 1 of the Application Form.
- 1.2 Where referenced within this document the SATRA Group of companies refers to SATRA Technology Centre Limited, SATRA Technology Europe Limited and SATRA Technology Services (Dongguan) Limited.
- 1.3 EU or UKCA module B Type Examination work will not be carried out for any Client until a fully completed and signed Application Form (and Certification Agreement) has been received by SATRA.
- a) and or reinstatement of a certificate
  - b) Reassessment due to changes in the management system or products certified
  - c) Compliance with any subpoena for documents or testimony relating to activities undertaken by SATRA

### 2. Client Responsibilities

#### The Client shall:

- 2.1 Undertake to pay all agreed fees and costs charged in conjunction with this application and where applicable to provide free of charge any samples required for testing purposes.

Additional fees may be incurred for work not included within the quote provided and for work required where non-conformances are identified. These may include, without limitation, costs arising from:

- a) Repeats of any part of the certification, due to the registration procedures and rules not being met
- b) Additional work due to suspension, withdrawal and or reinstatement of a certificate
- c) Reassessment due to changes in the management system or products certified
- d) Compliance with any subpoena for documents or testimony relating to activities undertaken by SATRA

- 2.2 Inform SATRA, without delay, of any changes that may affect its ability to conform with the certification requirements, including changes significantly affecting the product's design or specification, or changes in the standards to which compliance of the product is relevant, or in the case of any other information indicating that the product may no longer comply with the requirements of the certification scheme.

Examples of changes may include the following:

- a) the legal, commercial, organisational status or ownership,
- b) organisation and management (e.g., key managerial or technical staff),
- c) modifications to the product or the production method,
- d) contact address and manufacturing sites,
- e) major changes to the quality management system.

Where changes have taken place, the Client shall not release CE or UKCA marked products until the appropriate changes to the certified product, as agreed by SATRA and the Client, have been implemented.

- 2.3 Where applicable, provide access to certified products for surveillance activities.
- 2.4 Ensure that the certified product shall continue to fulfill the requirements of the product certification (e.g., levels or classifications achieved as part of the certification process).
- 2.5 Make all necessary arrangements for:
- a) the conduct of the evaluation and surveillance (if required), including provision for examining documentation and records, and access to the relevant equipment, location(s), area(s), personnel, and the Client's subcontractors;
  - b) the investigation of complaints;
  - c) the participation of observers, if applicable.
- 2.6 Provide any applicable information regarding known or potential hazards likely to be encountered by SATRA personnel as a result of handling or coming in to contact with submitted samples or during visits in order to allow SATRA to comply with Health and Safety legislation



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

- 2.7 Take all steps necessary to ensure that the manufacturing process, including the final inspection of PPE and tests, ensures the homogeneity of production and the conformity of PPE with the type described in the Module B Type Examination Certificate and with the relevant basic requirements of the PPE Regulation.
- 2.8 Ensure that any claims regarding certified products are consistent with the scope of product certification with respect to the identification of:
  - a) the product(s), process (es) or services(s) for which the certification is granted;
  - b) the applicable certification scheme; and,
  - c) the standard(s) and other normative document(s) (including date of publication) to which the product(s); process(es) or service(s) has been judged to comply.
- 2.9 Not use its product certification in such a manner as to bring SATRA into disrepute and does not make any statement regarding its product certification that SATRA may consider misleading or unauthorised.
- 2.10 Upon suspension, withdrawal, or termination of certification, the Client discontinues its use of all advertising matter that contains any reference thereto and acts as required by the certification scheme (e.g., the return of certification documents) and takes any other required measure.
- 2.11 Only provide copies of the certification documents to others, if the documents are reproduced in their entirety.
- 2.12 In referring to its product certification in communication media such as documents, brochures or advertising, the Client complies with the requirements of SATRA or as specified by the certification scheme.
- 2.13 Comply with any requirements that may be prescribed in the certification scheme relating to the use of marks of conformity, and on information related to the product. These being:
  - 2.13.1 The CE or UKCA Mark can only be applied to stationery and publicity material which relates to the products for which certification has been granted. This can include the internet, brochures, advertisements etc. We would advise any Client to contact us prior to printing if there is any doubt regarding the intended use. The misuse of the CE, UKCA or other marks could result in the issue of a requirement to withdraw offending items.
  - 2.13.2 Where possible the minimum height of the CE or UKCA mark must be no less than 5mm and shall only be increased in proportion.
  - 2.13.3 The CE, UKCA or other mark may not be used in any way that may be interpreted as misleading nor shall the client make any misleading statements regarding its certification
  - 2.13.4 The use of SATRA's Notified Body or Approved body number after the CE or UKCA mark is restricted to those products defined as Category III Products and where SATRA is responsible for Module C2 or Module D. However, it may be used on user information of all certified products as a means of identifying SATRA as the type approval body and the Module C2 or D body.
  - 2.13.5 Upon suspension or withdrawal of its certification, The Client shall discontinue its use of the CE or UKCA mark as directed by SATRA and shall amend all advertising matter when the scope of registration has been reduced. The Client shall ensure that the CE, UKCA or other marks are not used in such a manner that would bring SATRA into disrepute and lose public trust.
- 2.14 Uses certification only to indicate that products are certified as being in conformity with the PPE Regulation and where applicable specified standards.
- 2.15 Shall confirm that the samples submitted for any testing required as part of the certification process shall be representative of the product to be certified in respect of all its characteristics taken together, and be made from production tools and assembling methods used for the production run.
- 2.16 Retains a record of all non-conformities and complaints relating to certification requirements of the certified product(s) and makes these records available to SATRA when requested, and:
  - a) takes appropriate action with respect to such complaints about any deficiencies found in products that affect compliance with the requirements for certification;
  - b) documents the action taken.
- 2.17 Retain the EU or UKCA Certificate of Conformity (or a copy of it) for a minimum of 10 years after the product to which it relates is last placed on the market



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

### 3. SATRA Responsibilities

- 3.1 SATRA shall inform the Client of any changes that may affect the validity of the product certification.
- 3.2 After confirming the acceptance of the application, the SATRA Assessor shall discuss and agree with the Client the responsibility for carrying out the various tasks according to the requirements of Annex II of the PPE Regulation as applicable. Where testing is required, this shall be carried out in accordance with SATRA Technology Centre Limited's ISO 17025 Quality system and procedures. SATRA reserves the right to sub-contract testing, where this is required then this shall be agreed with the Client.
- 3.3 SATRA shall carry out the certification process against an agreed product standard (s) or specification (s) where possible. The normal route shall be to use an English language version of the appropriate European Harmonised, or UK designated standard. National forewords to such standards will not normally be considered unless specifically requested by the Client. Other standards or technical specifications may be used, where this is deemed necessary then it shall be by mutual agreement with the Client. Whichever option is chosen it shall satisfy all the relevant requirements of the PPE Regulation. This shall also include appropriate test data to demonstrate that the materials used to construct the products do not contain substances that may cause harm and that they are in compliance with the current requirements of all applicable product standards as well as the current version of Annex XVII of the EU and or UK REACH Regulation.
- 3.4 SATRA shall retain copies of technical files for a minimum of 10 years after the product is last placed on the market and/or the EU or UKCA Module B Type Examination certificate is cancelled, withdrawn or expires, whichever comes sooner. Such documentation shall be made available to the Surveillance Authorities upon demand.
- 3.5 Where review of an existing certificate is requested, the Assessor shall send the Client an appropriate application form for completion and return. On return of the completed application form, the Assessor shall decide on whether reduced Certification Procedures may be undertaken and shall document the decision.
- 3.6 Where an extension to an existing certificate is requested, the Assessor shall send the Client an appropriate application form for completion and return.
- 3.7 Where SATRA becomes aware that a registered Client has misused a certificate, schedule, logo or accreditation mark, the Client shall be required to ensure that the misuse is rectified. Incorrect references to the certification system or misleading use of information found in advertisements, catalogues etc. shall be dealt by suitable means including corrective action, publication of the transgression and, if necessary, legal action.
- 3.8 Suspension, termination, and withdrawal of certificates
- 3.8.1 Where a certificate is suspended, terminated, or withdrawn then the Client has the right to appeal. The appeal shall be received in writing, by SATRA, within twenty-eight working days of the Client having being informed of the intention to suspend, withdraw, or terminate the certificate.
- 3.8.2 The outcome of an appeal shall be final and binding on both parties and no counter claim by either party shall be accepted. Where an appeal is successful, the Clients costs may be reimbursed at the discretion of SATRA.
- 3.8.3 Suspension of certificates.
- 3.8.3.1 A Clients EU or UKCA Module B Type Examination Certificate may be suspended for the following reasons:
- Contravention of SATRA's rules and regulations relating to product certification;
  - Where effective corrective action is not implemented within an agreed timescale against a major non-compliance found during a surveillance visit.
  - Where significant non-homogeneity is highlighted during on-going surveillance.
- 3.8.3.2 SATRA shall inform the Client in writing that their certificate has been suspended, the reason(s) for the suspension and the actions required to reinstate the certificate.
- 3.8.3.3 SATRA shall inform the appropriate notifying authority when a Client's certificate has been suspended.
- 3.8.3.4 If product certification is reinstated after suspension, SATRA shall make all necessary modifications to formal product certification documents, public information, authorisations for use of marks, etc., in order to ensure all appropriate indications, exist that the product continues to be certified.
- 3.8.3.5 If a decision to reduce the scope of product certification is made as a condition of reinstatement, SATRA shall make all necessary modifications to formal product certification documents, public information, authorisations for use of marks, etc., in order to ensure the reduced scope of product certification is clearly communicated to the Client and clearly specified in product certification documentation and public information.





**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

### 3.8.4 Withdrawal or termination of certificates

#### 3.8.4.1 A certificate shall be withdrawn if:

- It is found that a condition of manufacture, design, materials, or packaging have been changed and therefore no longer comply with the requirements of the Directive or Regulation as applicable;
- The Client fails to settle their financial obligations to SATRA;
- The Client fails to effectively implement the actions agreed following the suspension of a certificate;
- Actions taken by the Client during their business activities that would bring SATRA and / or the Product Certification Scheme into disrepute;
- The Client does not wish to continue with certification;
- The Client goes out of business.

3.8.4.2 SATRA shall inform the Client in writing that their certificate has been withdrawn, the reason(s) for the withdrawal and any actions required.

3.8.4.3 SATRA shall inform the appropriate notifying authority when a Client's certificate has been withdrawn.

### 3.9 Confidentiality

3.9.1 The results of Product Certification activities shall be treated by SATRA as confidential. Results obtained shall only be passed to third parties with the permission of the Client that originally commissioned it, except for requests from enforcement and surveillance authorities.

Note: SATRA reserves the right to share information relating to certification within the SATRA Group of companies unless advised otherwise.

### 3.10 Complaints and Appeals

3.10.1 Upon receipt of a complaint or an appeal which relates to product certification activities, the Business area head or their nominated deputy shall deal with it in accordance with SATRA's complaints and appeals procedure.

3.10.2 Where the complaint or appeal relates to the on-going conformity of a product certified by SATRA, it is possible that any agreed remedial actions may involve recalling non-compliant products in which case SATRA shall require documented evidence of such a recall.

3.10.3 Complainants raising issues regarding a) products not being CE or UKCA -marked when they should be or b) EU or UKCA Type Examination certificates issued by other Notified or Approved Bodies shall be directed to the appropriate enforcement authority.

3.10.4 SATRA shall only accept written appeals received within twenty-eight days of the client being informed of the decision that gave rise to the appeal.

3.10.5 Full details of the SATRA Complaints and Appeals procedure are available on request.

3.11 SATRA shall retain in its archive for the period required by the relevant accreditation body all materials relating to the certificate. After which SATRA shall dispose of said materials unless instructed otherwise by the Client. All fees for carrying out such instructions will be invoiced to the Client.

## 4.0 SATRA Requirements

4.1 Any test reports submitted to SATRA in support of EU or UKCA type examination shall meet the following criteria:

- a) Reports shall reflect state of the art and be as current as possible, where reports are older than 5 years (60 months) then SATRA reserves the right to request additional supporting documentation, such as more recent check test data;
- b) Where not undertaken by SATRA, all testing and reporting shall be carried out by a laboratory that is independent and impartial to any economic operator of the finished product and considered as being competent to conduct the work. Accreditation of a laboratory to ISO 17025 by a National Accreditation Body that is recognised by INAB or UKAS (see ILAC website) for the work undertaken will be taken as evidence of competence as long as it can also demonstrate that it has knowledge of, and access to, any appropriate recommendation for use sheets and guidance papers endorsed by the European Commission or UK Government. In the absence of such accreditation, a report will be accepted only when competence has been demonstrated to the satisfaction of SATRA, via an audit visit and, where judged necessary, check testing.

Note, in either case if the laboratory is not a Notified or Approved Body, SATRA may commission limited check testing on safety critical properties;



**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

- c) Innocuousness test data which has been requested in addition to that required by the main European Harmonised or UK Designated Standard or performance specification. These additional innocuousness tests (i.e., not detailed in the product standard) need not be carried out by SATRA or an ISO 17025 accredited facility but it will be necessary to submit actual test data (declarations of conformity are not acceptable).
  - d) Reports shall contain where possible the following information:
    - (i) sample references given in any test report shall be the same as those detailed in the technical file,
    - (ii) reference to the manufacturer and manufacturing site(s),
    - (iii) identification of the organisation and personnel responsible for the test,
    - (iv) identification of the product(s) in accordance with the relevant technical specification,
    - (v) date(s) samples were received and the date(s) testing was undertaken,
    - (vi) details of samples received and the sampling procedure if applicable,
    - (vii) testing methods and procedures used according the relevant technical specification,
    - (viii) the results of all testing carried out, including analysis of these where relevant,
    - (ix) registration number of the Notified Body (when relevant),
    - (x) signature of the person authorised to sign such test reports;
  - e) The Test Report shall indicate compliance of the product(s) with the relevant clauses of the harmonised standard (s).
- 4.2 Copies of all test Reports used as part of the certification process shall be submitted to SATRA. Copies of Test Reports that form part of any on-going monitoring procedure should be retained by the manufacturer and made available on request.
- 4.3 All test reports submitted as part of the certification process shall, where applicable, include information relating to the use of uncertainty of measurement. When evaluating the suitability of results and reports SATRA will, where applicable to safety critical aspects of the product, take uncertainty of measurement into account. SATRA reserves the right to reject reports where the uncertainty of measurement cannot be determined for those tests/properties deemed by SATRA to be safety critical.
- 4.4 Where a technical file is required as part of the certification process then it shall include at least the following:
- a) name & address of the manufacturer;
  - b) name and address of the Authorised representative in the EU (if relevant);
  - c) full description(s) of the product(s) included within the technical file, including specifications, annotated drawings and comprehensive photographs of all styles;
  - d) full details of all materials and components used in the construction of the product (s) including specifications, and supplier details (name and postal address);
  - e) quality control procedures, and where appropriate, a copy of the ISO9001 certificate for the manufacturing site(s), this should include a description of the control and test facilities at the manufacturing site(s) that are in place in order to check compliance of production with the harmonized standards / technical specifications to ensure ongoing compliance;
  - f) details of proposed packaging and product marking, including label artwork;
  - g) copy (ies) of all applicable user information sheets, these shall comply with the requirements of the agreed product standard;
  - h) check list showing compliance with the applicable health and safety requirements, Annex II of the PPE Regulation;
  - i) all applicable test reports, references to materials on submitted test reports must correspond with those in the material specifications.
- 4.5 SATRA reserves the right to request additional supporting documentation including further testing, where the certification process becomes protracted.
- 5.0 Article 8 of the PPE Regulation – Obligations of manufacturers**
- 5.1 When placing PPE on the market, manufacturers shall ensure that it has been designed and manufactured in accordance with the applicable essential health and safety requirements set out in Annex II.
- 5.2 Manufacturers shall draw up the technical documentation referred to in Annex III ('technical documentation') and carry out the applicable conformity assessment procedure referred to in Article 19 or have it carried out.
- Where compliance of PPE with the applicable essential health and safety requirements has been demonstrated by the appropriate procedure, manufacturers shall draw up the EU or UKCA declaration of conformity referred to in Article 15 and affix the CE or UKCA marking referred to in Article 16.
- 5.3 Manufacturers shall keep the technical documentation and the EU declaration of conformity for 10 years after the PPE has been placed on the market.





**SATRA Technology Europe Ltd**  
 Bracetown Business Park  
 Clonee,  
 D15 YN2P, Ireland.  
 Tel: 00353(0)14372484  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satraeurope.com](http://www.satraeurope.com)

**SATRA Technology Centre Limited**  
 Wyndham Way, Telford Way,  
 Kettering, Northamptonshire,  
 NN16 8SD, United Kingdom.  
 Tel: +44 (0) 1536 410000  
 email: [info@satra.com](mailto:info@satra.com)  
[www.satra.com](http://www.satra.com)

- 5.4 Manufacturers shall ensure that procedures are in place for series production to remain in conformity with this Regulation. Changes in the design or characteristics of the PPE and changes in the harmonised or Designated standards or in other technical specifications by reference to which the conformity of the PPE is declared shall be adequately considered.
- When deemed appropriate regarding the risks presented by PPE, manufacturers shall, to protect the health and safety of consumers and other end-users, carry out sample testing of PPE made available on the market, investigate, and, if necessary, keep a register of complaints, of non-conforming PPE and PPE recalls, and shall keep distributors informed of any such monitoring.
- 5.5 Manufacturers shall ensure that the PPE which they place on the market bears a type, batch or serial number or other element allowing its identification, or, where the size or nature of the PPE does not allow it, that the required information is provided on the packaging or in a document accompanying the PPE.
- 5.6 Manufacturers shall indicate, on the PPE, their name, registered trade name or registered trade mark and the postal address at which they can be contacted or, where that is not possible, on its packaging or in a document accompanying the PPE. The address shall indicate a single point at which the manufacturer can be contacted. The contact details shall be in a language easily understood by end-users and market surveillance authorities.
- 5.7 Manufacturers shall ensure that the PPE is accompanied by the instructions and information set out in point 1.4 of Annex II in a language which can be easily understood by consumers and other end-users, as determined by the Member State concerned. Such instructions and information, as well as any labelling, shall be clear, understandable, intelligible, and legible.
- 5.8 The manufacturer shall either provide the EU or UKCA declaration of conformity with the PPE or include in the instructions and information set out in point 1.4 of Annex II the internet address at which the EU declaration of conformity can be accessed.
- 5.9 Manufacturers who consider or have reason to believe that PPE which they have placed on the market is not in conformity with this Regulation shall immediately take the corrective measures necessary to bring that PPE into conformity, to withdraw it or to recall it, as appropriate. Furthermore, where the PPE presents a risk, manufacturers shall immediately inform the competent national authorities of the Member States in which they made the PPE available on the market to that effect, giving details of the non-conformity and of any corrective measures taken.
- 5.10 Manufacturers shall, further to a reasoned request from a competent national authority, provide it with all the information and documentation, in paper or electronic form, necessary to demonstrate the conformity of the PPE with this Regulation, in a language which can be easily understood by that authority. They shall cooperate with that authority, at its request, on any action taken to eliminate the risks posed by PPE which they have placed on the market.

For more information, please contact:  
 E-mail: [ppe@satra.com](mailto:ppe@satra.com)  
 website: [www.satra.com](http://www.satra.com)



**Setino Hungary Kft.**

Tel:00361-349-1053 Fax:00361-340-8128

1107 Budapest, Száva u. 4/B

Website: [www.setino.com](http://www.setino.com)



## USER INFORMATION

# CE 2777

These products are classed as Category III Personal Protective Equipment (PPE) by the European PPE REGULATION 2016/425 and have been shown to comply with this Regulation through the Harmonised European Standard(s): EN ISO 21420:2020, EN ISO 374-1:2016+A1:2018, EN ISO 374-5:2016

### Product reference:

	XS	S	M	L	XL	XXL
Reference#	NPF3001	NPF3002	NPF3003	NPF3004	NPF3005	NPF3006

Disposable nitrile gloves (Violet Blue)

**Sizes available:** XS(5-6), S(6-7), M(7-8), L(8-9), XL (9-10), XXL (10-11)

### Intended Use:

The gloves are intended for protective purpose that is worn on the user's hands to make protection. It is ambidextrous and single use. Gloves have specified chemical protection function. The products are suitable for use in various fields such as garden, lab etc.

Performance and limitation of use –This product has been tested and achieved the following performance levels:

### Classification:

EN ISO 374-1:2016+A1:2018 /Type B	Level	EN ISO 374-4:2019 Degradation%	EN ISO 374-1:2016+A1:2018 /Type B
40% Sodium Hydroxide (K)	6	-58.9	 KPT
30% Hydrogen Peroxide (P)	2	-0.8	
37% Formaldehyde (T)	4	1.9	
<b>EN ISO 374-5:2016</b>			 Virus
Protection against Bacteria and Fungi	<b>Pass</b>		
Protection against Viruses	<b>Pass</b>		

EN ISO 374-1:2016+A1:2018 Permeation levels are based on breakthrough times as follows:

Permeation performance level	1	2	3	4	5	6
Measured breakthrough time (min)	> 10	> 30	> 60	> 120	> 240	> 480



EN ISO 374-4:2019 Degradation results indicate the change in puncture resistance of the gloves after exposure to the challenge chemical:

EN ISO 374-5:2016 The penetration resistance has been assessed under laboratory conditions and relates only to the tested specimen.”

“This information does not reflect the actual duration of protection in the workplace and the differentiation between mixtures and pure chemicals”

“The chemical resistance has been assessed under laboratory conditions from samples taken from the palm only (except in cases where the glove is equal to or over 400 mm - where the cuff is tested also) and relates only to the chemical tested. It can be different if the chemical is used in a mixture.”

“It is recommended to check that the gloves are suitable for the intended use because the conditions at the workplace may differ from the type test depending on temperature, abrasion and degradation.”

“When used, protective gloves may provide less resistance to the dangerous chemical due to changes in physical properties. Movements, snagging, rubbing, degradation caused by the chemical contact etc. may reduce the actual use time significantly. For corrosive chemicals, degradation can be the most important factor to consider in selection of chemical resistant gloves”

“Before usage, inspect the gloves for any defect or imperfections.”

Storage and transport: When not in use, store the product in a well-ventilated area away from extremes of temperature

Glove performance quoted is based on laboratory data and may not reflect the actual duration of protection in the workplace due to other factors influencing the performance such as temperature, abrasion, degradation etc.)

The glove does not contain any substances that are known to cause allergies.

The Gloves have no mechanical protection offered.

For single use only, do not littering.

Check for damage before use, do not use damaged gloves

#### Donning:

1. Remove all hand and wrist jewelry, and wash the hands before donning.
2. Place the gloves on the prepared work surface.
3. The user puts a glove on his/her dominant hand by grabbing it with the other hand, remembering to only touch the inside of the gloves, and slipping it over the dominant hand until it reaches finger level.
4. The wearer uses the gloved dominant hand to slip the other glove onto the non-dominant hand.
5. Once both gloves are on, the users can touch the outside of the gloves to ensure a proper fit

#### Doffing:

1. Using the dominant hand, users start by grabbing the outside of the glove on the non-dominant hand on the palm side near the cuff.
2. Pull the glove off the non-dominant hand and place it in the gloved hand, balling it up.
3. Slip two fingers under the cuff of the other hand glove and carefully peel it off the hand without touching the wrist, turning the remaining glove inside out as it is removed and in turn encasing the first glove.
4. The gloves can be disposed.

The DoC(declaration of conformity) will be shown on website: ([www.setino.com](http://www.setino.com))

Notified Body responsible for certification and ongoing conformity:



SATRA Technology Europe Ltd

Bracetown Business Park

Clonee, Dublin

D15 YN2P, Ireland (: 2777)

Product manufactured by: Setino Hungary Kft  
Budapest, Száva u. 4B, 1107, Hungary



YYYY-MM



YYMMDD



3years from manufacture date











## EU DECLARATION OF CONFORMITY

1) This declaration of conformity is issued under the sole responsibility of the manufacturer:

Company Name:	Setino Hungary Kft
Address:	Budapest, Száva u. 4B, 1107
Product code:	NPF 3001-3006 (Violet Blue )

2) insert description of the object of declaration

*Description of the Product:* Disposable Nitrile Gloves (Violet Blue)


3) The object of the declaration described in point 2 is in conformity with the relevant Union harmonisation legislation: **Personal Protective Equipment Regulation (EU) 2016/425**

4) References to the relevant harmonised standards used, including the date of the standard or references to the other technical specification, including the date of the specification, in relation to which conformity is declared:

Standards/ Technical Specifications applied	ENISO 21420:2020
	ENISO 374-1:2016+A1:2018(KPT)
	ENISO 374-2:2019
	EN16523-1:2015+A1:2018
	ENISO 374-4:2019
	ENISO 374-5:2016 Virus

5) Where applicable, the notified body SATRA Technology Europe Ltd, Bracetown Business Park, Clonree, Dublin 15D15 YN2PIreland; Notified Body Number: 2777 performed the EU examination (Module B) and issued the EU type- examination certificate (Reference to that certificate)

6) Where applicable, the PPE is subject to the conformity assessment procedure (either conformity to type based on internal production control plus supervised product checks at random intervals (module C2) or conformity to type based on quality assurance of the production process (module D under surveillance of the notified body: SATRA Technology Europe Ltd, Bracetown Business Park, Clonree, Dublin 15D15 YN2PIreland; Notified Body Number: 2777

Signed for and on behalf of	Setino Hungary Kft <b>SETINO HUNGARY KFT.</b>
Date of issue	June 08, 2023 <b>1107 Budapest, Száva u. 4/B</b> <b>Adószám: 13337634-2-42</b>
Name, function	LI LI, General Manager 

Sally Lei

**From:** renmin@honggray.com.cn  
**Sent:** Tuesday, June 20, 2023 5:40 PM  
**To:** Sally Lei  
**Cc:** Eric Guo; SATRA China Cert  
**Subject:** Re: Re: NPF 3001-3006 / CHC0351046

Sally,

Please also include English for the information on the side inner box (see below).

**[ee]** uurimis- ja kaitsekindad / nitril / pulbrivaba / tekstureeritud / ainult ühekordselt kasutatav / toote kvaliteet ei ole  
 kui pakend on kahjustatud / pikkus sobib käte kaitsmist nõudvate ülesannete jaoks

**[lt]** apžiūros ir apsauginės pirštinės / nitrilas / be pudros / tekstūruotos / tik vienkartiniam naudojimui / gamini  
 užtikrinama, jei pakuotė pažeista / ilgis tinkamas užduotims, kurioms reikia rankų apsaugos

**[nl]** onderzoeks- en beschermende handschoenen / nitril / poedervrij / gestructureerd / voor eenmalig gebruik / is  
 is niet gegarandeerd als de verpakking beschadigd is / lengte geschikt voor taken waarbij handbescherming vereist

**[cz]** diagnostické a ochranné rukavice / nitril / bezpudrové / pro jednorázové použití / kvalitu výrobku nelze za  
 poškození obalu / délka vhodná pro úkony, které vyžadují ochranu rukou /

**[sl]** diagnostične in zaščitne rokavice / nitril / nepudrane / za enkratno uporabo / kakovost izdelka ni zagotovljeni  
 v primeru poškodovane embalaže / dolžina, ustrezna glede na dejavnosti zahtevajoče zaščito rok /

**[sk]** diagnostické a ochranné rukavice / nitril / bezpúdrové / pre jednorazové použitie / kvalitu výrobku nie je  
 v prípade poškodenia obalu / dĺžka vhodná pre úlohy, ktoré vyžadujú ochranu rúk /

**[srbs]** rukavice dijagnostičke i zaštitne / nitrilne / bez pudera / za jednokratno korišćenje / kvalitet proizvoda s  
 u slučaju oštećenja pakovanja / dužina pogodna za aktivnosti koje zahtevaju zaštitu ruku /

English version has been updated in the inner box as below.

**[en]** Examination and protective gloves / nitrile / powder-free / textured / for single use only / product quality is r  
 ensured if the package is damaged / length suitable for tasks that require hand protection /

renmin@honggray.com.cn

**From:** [renmin@honggray.com.cn](mailto:renmin@honggray.com.cn)  
**Date:** 2023-06-19 17:45  
**To:** Sally Lei  
**CC:** [ericg](#); [SATRA China Cert](#)  
**Subject:** Re: NPF 3001-3006 / CHC0351046

Sally,

证书草稿稍后确认，其他comment的信息更新了。

Confirm the UI SHEET IS SUPPLIED INSIDE THE DISPENSER BOX.

CIMAC reference code :STBKNT35 is product's Item No

renmin@honggray.com.cn

**From:** [Sally Lei](#)

**Sally Lei**

---

**From:** renmin@honggray.com.cn  
**Sent:** Monday, June 19, 2023 5:46 PM  
**To:** Sally Lei  
**Cc:** Eric Guo; SATRA China Cert  
**Subject:** Re: NPF 3001-3006 / CHC0351046  
**Attachments:** ASTMD 6978.pdf; update-artwork 01.pdf; update-artwork 02.pdf

Sally,

证书草稿稍后确认，其他comment的信息更新了。

Confirm the UI SHEET IS SUPPLIED INSIDE THE DISPENSER BOX.

CIMAC reference code :STBKNT35 is product's Item No

---

renmin@honggray.com.cn

---

**From:** [Sally Lei](#)  
**Date:** 2023-06-16 11:37  
**To:** [renmin@honggray.com.cn](mailto:renmin@honggray.com.cn)  
**CC:** [Eric Guo](#); [SATRA China Cert](#)  
**Subject:** NPF 3001-3006 / CHC0351046  
Hello Renmin,

请确认附档的证书草稿。

同时请根据审核意见报告修改技术文件，谢谢

Best regards,

Sally Lei  
China PPE Certification

\*\*\* SATRA Webinar and online resources 网络研讨会及线上资源 <https://www.satra.com/resources/> \*\*\*

**SATRA Technology Services (Dongguan) Limited**

东莞赛卓检测技术服务有限公司

Tel : +86 769 2288 8020 ext. 5037

Unit 110 Xinzhongyin Garden, Hongwei Rd, Xiping, Nancheng District, Dongguan, Guangdong, China

中国广东省东莞市南城区西平宏伟路新中银花园110商铺



[www.satra.com](http://www.satra.com) / [www.satra.cn](http://www.satra.cn)

---

**From:** Emma Kwong <emmak@satrafe.com>

**Sent:** Monday, June 12, 2023 10:36 AM

**To:** renmin@honggray.com.cn

**Cc:** Ting Huang <tingh@satrafe.com>; Eric Guo <ericg@satrafe.com>; Sally Lei <sallyl@satrafe.com>; SATRA China Cert <cert@satrafe.com>

**Subject:** Re: 3张客户延展--加急 CHC0351045/ CHC0351046/ CHC0351047

**Importance:** High

Hello Renmin,





Testing. Development. Problem Solving.


January 5, 2021

**TEST REPORT****PN 156884****PHARMACEUTICAL SERVICES**


Prepared For:

Renmin  
Shijiazhuang Hongray Group Co., Ltd.  
South Tongda Rd.,  
East Dist. Jinzhou City,  
Hebei, 052260  
China

Prepared By:

  
Tiffany Heller  
Manager, Pharmaceutical Services

Approved By:

  
Ana C Barbur, M.S.  
Vice President, Analytical & Chemical Services

Rev 101218



An A2LA ISO 17025 Accredited Testing Laboratory — Certificate Numbers 255.01 & 255.02  
ISO 9001:2015 Registered

**ISO 9001:2015**  
Registered

Letters and reports are for the exclusive use of the clients to whom they are addressed and shall not be reproduced, except in full, without the written permission of Akron Rubber Development Laboratory, Inc. (ARDL). The information contained herein applies to the specific material, products or processes tested or evaluated. No warranty of any kind is herein construed or implied. The liability of ARDL, Inc. shall be limited to the amount of consideration paid for services. ARDL, Inc. is ISO 17025 accredited by A2LA for the test methods listed on the referenced certificates.



Testing. Development. Problem Solving.

January 5, 2021

Renmin  
Shijiazhuang Hongray Group Co., Ltd.

PN 156884

**SUBJECT:** Permeation testing per ASTM D6978 on sample submitted by the above company.

**RECEIVED:** One (1) glove type identified as; Powder Free Nitrile Examination Gloves – Extended Cuff, Device Identifier Hongray: NEGPF2001-2004, Corresponding Devices ID, NEOBEX: 1530-1021000B-E.

**TEST CHEMICALS:**

Table 1. List of the Testing Drugs and their Sources

TESTING CHEMOTHERAPY DRUGS	DRUG SOURCE
Busulfan, 6 mg/ml (6,000 ppm)	Sigma Aldrich; Lot# BCBZ9160; Expiration 01/2022
Carboplatin, 10 mg/ml (10,000 ppm)	Teva; Lot# 19K11KA; Expiration 11/2021
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	USP; Lot# R116Y0; Expiration 07/2021
Cisplatin, 1.0 mg/ml (1,000 ppm)	Accord; Lot# P2001296; Expiration 01/2022
Cyclophosphamide (Cytosan), 20.0 mg/ml (20,000 ppm)	Accord; Lot# 19112225; Expiration 10/2021
Cytarabine, 100 mg/ml (100,000 ppm)	Sigma Aldrich; Lot# MKCJ9806; Expiration 01/2022
Dacarbazine, 10.0 mg/ml (10,000 ppm)	Teva; Lot# 31325414B; Expiration 09/2021
Daunorubicin HCl, 5 mg/ml (5,000 ppm)	USP; Lot# M1M099; Expiration 02/2021
Docetaxel, 10 mg/ml (10,000 ppm)	LC Labs; Lot# BDC-117; Expiration 01/2025
Doxorubicin HCl, 2.0 mg/ml (2,000 ppm)	WestWard; Lot# BJ0051; Expiration 06/2021
Epirubicin HCl, 2 mg/ml (2,000 ppm)	Actavis; Lot# 7U15152; Expiration 10/2020
Etoposide, 20.0 mg/ml (20,000 ppm)	Teva; Lot# 31325485B; Expiration 07/2021
Fludarabine, 25 mg/ml (25,000 ppm)	USP; Lot# H1K220; Expiration 08/2021
Fluorouracil, 50.0 mg/ml (50,000 ppm)	Accord; Lot# P2001167; Expiration 01/2022
Gemcitabine, 38 mg/ml (38,000 ppm)	LC Labs; Lot# GMC-105; Expiration 1/6/2025
Idarubicin HCl, 1 mg/ml (1,000 ppm)	Teva; Lot# 31325163B; Expiration 05/2021
Ifosfamide, 50 mg/ml (50,000 ppm)	Baxter Healthcare; Lot# 9A018G; Expiration 01/2022
Irinotecan, 20 mg/ml (20,000 ppm)	USP; Lot# R10230; Expiration 12/2020
Melphalan, 5 mg/ml (5,000 ppm)	USP; Lot# R086P0; Expiration 02/2021
Methotrexate, 25 mg/ml (25,000 ppm)	Teva; Lot# 19F06NB; Expiration 06/2021
Mitomycin C, 0.5 mg/ml (500 ppm)	USP; Lot# R07240; Expiration 07/2021
Mitoxantrone, 2 mg/ml (2,000 ppm)	Sigma Aldrich; Lot# MKBR2210V; Expiration 02/2021
Paclitaxel, 6.0 mg/ml (6,000 ppm)	Teva; Lot# 19K24KA; Expiration 11/2021
Rituximab, 10 mg/ml (10,000 ppm)	Hetero Healthcare; Batch# RB1921B; Expiration 08/2021
ThioTepa, 10.0 mg/ml (10,000 ppm)	USP; Lot # R11380; Expiration 04/2021
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	Hospira; Lot# G057139AA; Expiration 03/31/2021

\*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.

NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.\*

www.ardl.com | 2887 Gilchrist Rd. | Akron, Ohio 44305 | answers@ardl.com | Toll Free (800) 830-ARDL

Fax (330) 794-6610 | Worldwide (330) 794-6600

January 5, 2021

Renmin  
Shijiazhuang Hongray Group Co., Ltd.

PN 156884

**COLLECTION MEDIA:**

Table 2. Collection Media for Test Drug

TEST DRUG AND CONCENTRATION	COLLECTION MEDIUM
Busulfan, 6 mg/ml (6,000 ppm)	Distilled Water
Carboplatin, 10 mg/ml (10,000 ppm)	Distilled Water
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	10% Ethanol Aqueous Solution
Cisplatin, 1.0 mg/ml (1,000 ppm)	Distilled Water
Cyclophosphamide (Cytosan), 20.0 mg/ml (20,000 ppm)	Distilled Water
Cytarabine, 100 mg/ml (100,000 ppm)	Distilled Water
Dacarbazine, 10.0 mg/ml (10,000 ppm)	Distilled Water
Daunorubicin HCl, 5 mg/ml (5,000 ppm)	Distilled Water
Docetaxel, 10 mg/ml (10,000 ppm)	Distilled Water
Doxorubicin HCl, 2.0 mg/ml (2,000 ppm)	Distilled Water
Epirubicin HCl, 2 mg/ml (2,000 ppm)	Distilled Water
Etoposide, 20.0 mg/ml (20,000 ppm)	Distilled Water
Fludarabine, 25 mg/ml (25,000 ppm)	Distilled Water
Fluorouracil, 50.0 mg/ml (50,000 ppm)	9.20 pH Sodium Hydroxide Solution
Gemcitabine, 38 mg/ml (38,000 ppm)	Distilled Water
Idarubicin HCl, 1 mg/ml (1,000 ppm)	Distilled Water
Ifosfamide, 50 mg/ml (50,000 ppm)	Distilled Water
Irinotecan, 20 mg/ml (20,000 ppm)	Distilled Water
Melphalan, 5 mg/ml (5,000 ppm)	Distilled Water
Methotrexate, 25 mg/ml (25,000 ppm)	Distilled Water
Mitomycin C, 0.5 mg/ml (500 ppm)	Distilled Water
Mitoxantrone, 2 mg/ml (2,000 ppm)	Distilled Water
Paclitaxel, 6.0 mg/ml (6,000 ppm)	30% Methanol Aqueous Solution
Rituximab, 10 mg/ml (10,000 ppm)	Distilled Water
ThioTepa, 10.0 mg/ml (10,000 ppm)	Distilled Water
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	Distilled Water

**TESTING CONDITIONS:**

Standard Test Method Used:	ASTM D6978
Analytical Method:	UV/VIS Spectrometry
Testing Temperature:	35.0°C ± 2.0
Collection System:	Closed Loop
Specimen Area Exposed:	5.067 cm <sup>2</sup>
Selected Data Points:	25/test
Number of Specimens Tested:	3/test
Location Sampled From:	Cuff



January 5, 2021

Renmin  
Shijiazhuang Hongray Group Co., Ltd.

PN 156884

**DETECTION METHOD OF CHEMICAL PERMEATION:****UV/VIS ABSORPTION SPECTROMETRY:**

Instrument: Perkin Elmer UV/VIS Spectrometer Lambda 25

UV/VIS Absorption Spectrometry was used to measure the absorbance of test chemicals, which permeated through the specimens into the collection medium. The collection medium was circulated in a closed loop through the testing period. Data collection was performed according to the programmed schedule by means of UV Winlab software from the Perkin Elmer Corporation. The list of the characteristic wavelengths is shown below.

Table 3. Characteristic Wavelengths used in UV/VIS Absorption Spectrometry

TESTING DRUG	WAVELENGTH (nm)
Busulfan, 6 mg/ml (6,000 ppm)	197
Carboplatin, 10 mg/ml (10,000 ppm)	192
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	229
Cisplatin, 1.0 mg/ml (1,000 ppm)	199
Cyclophosphamide (Cytosan), 20.0 mg/ml (20,000 ppm)	200
Cytarabine, 100 mg/ml (100,000 ppm)	272
Dacarbazine, 10.0 mg/ml (10,000 ppm)	320
Daunorubicin HCl, 5 mg/ml (5,000 ppm)	269
Docetaxel, 10 mg/ml (10,000 ppm)	231
Doxorubicin HCl, 2.0 mg/ml (2,000 ppm)	232
Epirubicin HCl, 2 mg/ml (2,000 ppm)	233 & 253
Etoposide, 20.0 mg/ml (20,000 ppm)	205
Fludarabine, 25 mg/ml (25,000 ppm)	261
Fluorouracil, 50.0 mg/ml (50,000 ppm)	269
Gemcitabine, 38 mg/ml (38,000 ppm)	202
Idarubicin HCl, 1 mg/ml (1,000 ppm)	257
Ifosfamide, 50 mg/ml (50,000 ppm)	200
Irinotecan, 20 mg/ml (20,000 ppm)	200
Melphalan, 5 mg/ml (5,000 ppm)	260
Methotrexate, 25 mg/ml (25,000 ppm)	303
Mitomycin C, 0.5 mg/ml (500 ppm)	217
Mitoxantrone, 2 mg/ml (2,000 ppm)	245
Paclitaxel, 6.0 mg/ml (6,000 ppm)	231
Rituximab, 10 mg/ml (10,000 ppm)	192
ThioTepa, 10.0 mg/ml (10,000 ppm)	199
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	220

\*ARL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.

NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.\*

January 5, 2021

Renmin  
Shijiazhuang Hongray Group Co., Ltd.

PN 156884

**SAMPLE CHARACTERISTICS:**

Examination Gloves – Extended Cuff, Device Identifier

Hongray: NEGPF2001-2004, Corresponding Devices ID, NEOBEX: 1530-1021000B-E.

Testing Drug	Thickness (mm)			Average (mm)
	Sample 1	Sample 2	Sample 3	
Busulfan	0.080	0.076	0.079	0.078
Carboplatin	0.079	0.076	0.081	0.079
Carmustine	0.093	0.082	0.081	0.086
Cisplatin	0.093	0.079	0.081	0.084
Cyclophosphamide (Cytosan)	0.084	0.079	0.083	0.082
Cytarabine	0.085	0.079	0.088	0.084
Dacarbazine	0.085	0.091	0.078	0.085
Daunorubicin HCl	0.083	0.077	0.092	0.084
Docetaxel	0.083	0.092	0.081	0.085
Doxorubicin HCl	0.081	0.072	0.083	0.078
Epirubicin HCl	0.081	0.074	0.081	0.079
Etoposide	0.083	0.080	0.081	0.081
Fludarabine	0.081	0.073	0.082	0.079
Fluorouracil	0.090	0.074	0.084	0.083
Gemcitabine	0.080	0.073	0.082	0.078
Idarubicin HCl	0.092	0.079	0.081	0.084
Ifosfamide	0.084	0.074	0.081	0.080
Irinotecan	0.081	0.080	0.079	0.080
Melphalan	0.082	0.083	0.094	0.086
Methotrexate	0.081	0.077	0.092	0.083
Mitomycin C	0.079	0.076	0.083	0.079
Mitoxantrone	0.082	0.083	0.076	0.081
Paclitaxel	0.087	0.081	0.083	0.084
Rituximab	0.081	0.081	0.079	0.080
ThioTepa	0.080	0.084	0.081	0.081
Vincristine Sulfate	0.080	0.087	0.079	0.082
<b>Weight/Unit Area (g/m<sup>2</sup>)</b>	<b>74.3</b>			

**RESULTS:**

Table 5.1 Permeation Test Results on testing of: Powder Free Nitrile Examination Gloves – Extended Cuff, Device Identifier

Hongray: NEGPF2001-2004, Corresponding Devices ID, NEOBEX: 1530-1021000B-E.

TEST CHEMOTHERAPY DRUGS	AVERAGE BREAKTHROUGH DETECTION TIME (Specimen1/2/3) (Minutes)	AVERAGE STEADY STATE PERM. RATE (Specimen1/2/3) (µg/cm <sup>2</sup> /minute)	OTHER OBSERVATIONS
Busulfan, 6 mg/ml (6,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Carboplatin, 10 mg/ml (10,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Carmustine (BCNU), 3.3 mg/ml (3,300 ppm)	33.1 (36.3, 34.1, 33.1)	1.1 (1.0, 1.1, 1.1)	Moderate swelling and no degradation
Cisplatin, 1.0 mg/ml (1,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Cyclophosphamide (Cytosan), 20.0 mg/ml (20,000 ppm)	>240 min.	N/A	Slight swelling and no degradation

\*ARL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.

NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.\*

January 5, 2021

Renmin  
Shijiazhuang Hongray Group Co., Ltd.

PN 156884

**RESULTS cont.:**

Table 5.2 Permeation Test Results on testing of: Powder Free Nitrile Examination Gloves – Extended Cuff, Device Identifier  
 Hongray: NEGPF2001-2004, Corresponding Devices ID, NEOBEX: 1530-102 1000B-E.

TEST CHEMOTHERAPY DRUGS	AVERAGE BREAKTHROUGH DETECTION TIME (Specimen1/2/3) (Minutes)	AVERAGE STEADY STATE PERM. RATE (Specimen1/2/3) ( $\mu\text{g}/\text{cm}^2/\text{minute}$ )	OTHER OBSERVATIONS
Cytarabine, 100 mg/ml (100,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Dacarbazine, 10.0 mg/ml (10,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Daunorubicin HCl, 5 mg/ml (5,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Docetaxel, 10 mg/ml (10,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Doxorubicin HCl, 2.0 mg/ml (2,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Epirubicin HCl, 2 mg/ml (2,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Etoposide, 20.0 mg/ml (20,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Fludarabine, 25 mg/ml (25,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Fluorouracil, 50.0 mg/ml (50,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Gemcitabine, 38 mg/ml (38,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Idarubicin HCl, 1 mg/ml (1,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Ifosfamide, 50 mg/ml (50,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Irinotecan, 20 mg/ml (20,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Melphalan, 5 mg/ml (5,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Methotrexate, 25 mg/ml (25,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Mitomycin C, 0.5 mg/ml (500 ppm)	>240 min.	N/A	Slight swelling and no degradation
Mitoxantrone, 2 mg/ml (2,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
Paclitaxel, 6.0 mg/ml (6,000 ppm)	>240 min.	N/A	Moderate swelling and no degradation
Rituximab, 10 mg/ml (10,000 ppm)	>240 min.	N/A	Slight swelling and no degradation
ThioTepa, 10.0 mg/ml (10,000 ppm)	68.1 (68.1,76.8,78.1)	0.7 (0.8,0.7,0.6)	Slight swelling and no degradation
Vincristine Sulfate, 1.0 mg/ml (1,000 ppm)	>240 min.	N/A	Slight swelling and no degradation

\*ARDL is ISO 17025 accredited by A2LA for the test methods listed on the certificates referenced on page one. Unless specified, the current specification version is used.  
 NOTE: Non-ISO 17025 accredited test methods are designated with the ^ symbol to differentiate from ISO 17025 accredited methods in the body of the test report.\*